Clinical MS Research Group
Our single objective: to prevent and reverse disability for everyone with multiple sclerosis, neuromyelitis optica and MOG associated disease.
Research Themes
We are achieving this objective through six themes:
-
Personalising Treatments through Big Data and AI
-
Discovering and Proving New Repair therapies
-
Our Visual and MRI Outcome Development Program
-
Studying Children with MS, NMO and related conditions
-
Study ageing in multiple sclerosis
-
Measuring and sustainably addressing healthcare inequalities.
Currently our work is focused on:
-
Improving the availability of data in electonic health records in the UK for MS researchers
-
Using real-world data to answer important questions about how best to use MS therapies
-
Exploring how best to measure remyelination in adults and children with MS
-
Investigating natural remyelination in people with MS
-
Doing clinical trials to identify drugs which promote endogenous remyelination in people with MS
Read more here.
Featured News
CCMSR Members Celebrated!
4th November 2024
We are excited to announce that two members of our group, Dr Chris McMurran and Dr Jonathon Holland, have been awarded the Vera Down grant. This award is “to assist research into neurological disorders", which Dr McMurran and Dr Holland will be using to support a novel project that will study the association between biological age and remyelination in people living with MS, aiming to identify reasons for remyelination failure and novel approaches to treating people with MS. Read more here.
23rd August 2024
It is with great pleasure that we announce that we have completed recruitment of our CCMR2 trial, which will assess the effectiveness of metformin and clemastine to repair myelin damage in people living with multiple sclerosis.
Learn more about this trial here.
22nd May 2024
A recent publication, led by Dr Chris McMurran, has found that the remyelination effects observed in CCMR1 were sustained beyond the initial trial period. The paper concludes that "this supports the increasingly clear position that pharmacological promotion of remyelination in people living with multiple sclerosis is possible and indicates a sustainability to repair following treatment with a remyelinating drug".
Continue reading here.